Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090628 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL6152672 | 0.87 | CHRNB2 (0.58) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL4965472 | 0.87 | CHRNB2 (0.58) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL4962052 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL11659133 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL4961033 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL5552804 | 0.79 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4961704 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL4958023 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4MEN1KMT2AGAA | |
| SCHEMBL4962002 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719022-A2 | NITROGEN-CONTAINING HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC Ireland Limited (IE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4482913-B1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250185505-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2025-06-05 | — | — | US | disclosed |
| WO-2023161168-A1 | AROMATIC HETREOCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161167-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-1084109-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1084109-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062883-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| US-4031237-A | DIELS-ALDER CONDENSATION | MOBIL OIL CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | CHRNB2 498/4885CHRNA4 345/4885MEN1 3324/4885 |
| US-20250185505-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | NES, NUDC, HCN2 | CHRNB2 834/4885CHRNA4 641/4885MEN1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.